“There’s a lot of clinical utility to genetic testing, and there are familial implications and clinical trial implications,” explains Neal Shore, MD.
Neal Shore, MD, explains how genetic testing has become an essential component of the treatment paradigm for patients with prostate cancer. Shore is co-chairing the CME program at the 2022 LUGPA Annual Meeting, which will include a session on genetic testing. Shore is medical director for the Carolina Urologic Research Center and chief medical officer, Surgical Oncology and Urology, for Genesis Care (US).
Expert explains sequencing strategies in patients with mCRPC
November 13th 2022For patients with mCRPC who experience disease progression on novel hormonal agents (NHAs) and androgen deprivation therapy, it is important to consider when the NHA was received and whether docetaxel has been administered, explains Evan Y. Yu, MD.
Dr. Alicia Morgans details decision between doublets and triplets in mCSPC
November 12th 2022ADT intensification through doublet and triplet regimens has become standard for most patients with metastatic castration-sensitive prostate cancer, Alicia Morgans, MD, MPH, explained in a presentation at the 2022 LUGPA Annual Meeting.
Tips for optimizing an advanced prostate cancer clinic
November 11th 2022In an interview during the 2022 LUGPA Annual Meeting, Jason M. Hafron, MD, shared advice on optimizing advanced prostate cancer clinics, recapped the biggest advances in urologic cancer treatment in 2022, and discussed how Jelmyto treatment for UTUC has evolved over time.
Dr. Siefker-Radtke on the biggest recent advances in urothelial cancer care
November 11th 2022"It really is a fun time to be doing urothelial cancer research, as we see patients living longer, with more durable responses, impacting their overall survival and long-term outcomes," says Arlene Siefker-Radtke, MD.
2 Clarke Drive
Cranbury, NJ 08512